References
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424.
- Budny A, Kozłowski P, Kamińska M, Jankiewicz M, Kolak A, Budny B et al.: [Epidemiology and risk factors of hepatocellular carcinoma]. Pol Merkur Lekarski 2017; 43: 133–139.
- Jindal A, Thadi A, Shailubhai K: Hepatocellular carcinoma: etiology and current and future drugs. J Clin Exp Hepatol 2019; 9: 221–232.
- Fujiwara N, Friedman SL, Goossens N, Hoshida Y: Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol 2018; 68: 526–549.
- Society AC: Liver cancer risk factors 2019 [updated April 1, 2019. Online: https://www.cancer.org/cancer/liver-cancer/causes-risks-prevention/risk-factors.html].
- Shafizadeh N, Kakar S: Hepatocellular carcinoma: histologic subtypes. Surg Pathol Clin 2013; 6: 367–384.
- El Jabbour T, Lagana SM, Lee H: Update on hepatocellular carcinoma: Pathologists’ review. World J Gastroenterol 2019; 25: 1653–1665.
- Torbenson MS: Morphologic subtypes of hepatocellular carcinoma. Gastroenterol Clin North Am 2017; 46: 365–391.
- Han YS, Choi DL, Park JB: Cirrhotomimetic type hepatocellular carcinoma diagnosed after liver transplantation – eighteen months of followup: a case report. Transplant Proc 2008; 40: 2835–2836.
- Okuda K, Noguchi T, Kubo Y, Shimokawa Y, Kojiro M, Nakashima T: A clinical and pathological study of diffuse type hepatocellular carcinoma. Liver 1981; 1: 280–289.
- Kim YK, Han YM, Kim CS: Comparison of diffuse hepatocellular carcinoma and intrahepatic cholangiocarcinoma using sequentially acquired gadolinium-enhanced and Resovist-enhanced MRI. Eur J Radiol 2009; 70: 94–100.
- Rogoveanu I, Văcaru D, Gheonea D, Georgescu CV, Comănescu V, Ciurea T: Diagnostic particularities in primitive diffuse form hepatocellular carcinoma associated with portal vein thrombosis. Rom J Morphol Embryol 2005; 46: 317–321.
- Jakate S, Yabes A, Giusto D, Naini B, Lassman C, Yeh MM et al.: Diffuse cirrhosis-like hepatocellular carcinoma: a clinically and radiographically undetected variant mimicking cirrhosis. Am J Surg Pathol 2010; 34: 935–341.
- Ho CM, Liang PC, Hu RH, Lee PH: Diffuse cirrhosis-like recurrence of hepatocellular carcinoma after curative resection. Surgery 2016; 160: 519–520.
- Poddar N, Avezbakiyev B, He Z, Jiang M, Gohari A, Wang JC: Hepatocellular carcinoma presenting as an incidental isolated malignant portal vein thrombosis. J Gastrointest Cancer 2012; 43: 486–489.
- Trevisani F, Caraceni P, Bernardi M, D’Intino PE, Arienti V, Amorati P et al.: Gross pathologic types of hepatocellular carcinoma in Italian patients. Relationship with demographic, environmental, and clinical factors. Cancer 1993; 72: 1557–1563.
- Kanematsu M, Semelka RC, Leonardou P, Mastropasqua M, Lee JK: Hepatocellular carcinoma of diffuse type: MR imaging findings and clinical manifestations. J Magn Reson Imaging 2003; 18: 189–195.
- Reynolds AR, Furlan A, Fetzer DT, Sasatomi E, Borhani AA, Heller MT et al.: Infiltrative hepatocellular carcinoma: what radiologists need to know. Radiographics 2015; 35: 371–386.
- Demirjian A, Peng P, Geschwind JF, Cosgrove D, Schutz J, Kamel IR et al.: Infiltrating hepatocellular carcinoma: seeing the tree through the forest. J Gastrointest Surg 2011; 15: 2089–2097.
- Sereni CP, Rodgers SK, Kirby CL, Goykhman I: Portal vein thrombus and infiltrative HCC: a pictoral review. Abdom Radiol (NY) 2017; 42: 159–170.
- Benvegnù L, Noventa F, Bernardinello E, Pontisso P, Gatta A, Alberti A: Evidence for an association between the aetiology of cirrhosis and pattern of hepatocellular carcinoma development. Gut 2001; 48: 110–115.
- Myung SJ, Yoon JH, Kim KM, Gwak GY, Kim YJ, Yu JW et al.: Diffuse infiltrative hepatocellular carcinomas in a hepatitis B-endemic area: diagnostic and therapeutic impediments. Hepatogastroenterology 2006; 53: 266–270.
- Kneuertz PJ, Demirjian A, Firoozmand A, Corona-Villalobos C, Bhagat N, Herman J et al.: Diffuse infiltrative hepatocellular carcinoma: assessment of presentation, treatment, and outcomes. Ann Surg Oncol 2012; 19: 2897–2907.
- Farinati F, Marino D, De Giorgio M, Baldan A, Cantarini M, Cursaro C et al.: Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol 2006; 101: 524–532.
- Tada T, Kumada T, Toyoda H, Kiriyama S, Sone Y, Tanikawa M et al.: Relationship between Lens culinaris agglutinin-reactive alpha-fetoprotein and pathologic features of hepatocellular carcinoma. Liver Int 2005; 25: 848–853.
- Okuda H, Saito A, Shiratori K, Yamamoto M, Takasaki K, Nakano M: Clinicopathologic features of patients with primary malignant hepatic tumors seropositive for alpha-fetoprotein-L3 alone in comparison with other patients seropositive for alpha-fetoprotein-L3. J Gastroenterol Hepatol 2005; 20: 759–764.
- Okuda H, Nakanishi T, Takatsu K, Saito A, Hayashi N, Yamamoto M et al.: Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone. J Gastroenterol Hepatol 2002; 17: 772–778.
- Yu NC, Chaudhari V, Raman SS, Lassman C, Tong MJ, Busuttil RW et al.: CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clin Gastroenterol Hepatol 2011; 9: 161–167.
- Lim S, Kim YK, Park HJ, Lee WJ, Choi D, Park MJ: Infiltrative hepatocellular carcinoma on gadoxetic acid-enhanced and diffusion-weighted MRI at 3.0T. J Magn Reson Imaging 2014; 39: 1238–1245.
- Halıloğlu N, Özkavukcu E, Erden A, Erden I: MR imaging in diffuse-type hepatocellular carcinoma with synchronous portal vein thrombi. Turk J Gastroenterol 2011; 22: 158–164.
- Park YS, Lee CH, Kim BH, Lee J, Choi JW, Kim KA et al.: Using Gd-EOBDTPA-enhanced 3-T MRI for the differentiation of infiltrative hepatocellular carcinoma and focal confluent fibrosis in liver cirrhosis. Magn Reson Imaging 2013; 31: 1137–1142.
- Rosenkrantz AB, Lee L, Matza BW, Kim S: Infiltrative hepatocellular carcinoma: comparison of MRI sequences for lesion conspicuity. Clin Radiol 2012; 67: e105–111.
- Choi JY, Lee JM, Sirlin CB: CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology 2014; 273: 30–50.
- Willatt JM, Hussain HK, Adusumilli S, Marrero JA: MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology 2008; 247: 311–130.
- Dodd GD 3rd, Memel DS, Baron RL, Eichner L, Santiguida LA: Portal vein thrombosis in patients with cirrhosis: does sonographic detection of intrathrombus flow allow differentiation of benign and malignant thrombus? AJR Am J Roentgenol 1995; 165: 573–577.
- Margini C, Berzigotti A: Portal vein thrombosis: The role of imaging in the clinical setting. Dig Liver Dis 2017; 49: 113–120.
- Tublin ME, Dodd GD 3rd, Baron RL: Benign and malignant portal vein thrombosis: differentiation by CT characteristics. AJR Am J Roentgenol 1997; 168: 719–723.
- Raza SA, Jang HJ, Kim TK: Differentiating malignant from benign thrombosis in hepatocellular carcinoma: contrast-enhanced ultrasound. Abdom Imaging 2014; 39: 153–161.
- Tarantino L, Ambrosino P, Di Minno MN: Contrast-enhanced ultrasound in differentiating malignant from benign portal vein thrombosis in hepatocellular carcinoma. World J Gastroenterol 2015; 21: 9457–9460.
- Shah ZK, McKernan MG, Hahn PF, Sahani DV: Enhancing and expansile portal vein thrombosis: value in the diagnosis of hepatocellular carcinoma in patients with multiple hepatic lesions. AJR Am J Roentgenol 2007; 188: 1320–1323.
- Catalano OA, Choy G, Zhu A, Hahn PF, Sahani DV: Differentiation of malignant thrombus from bland thrombus of the portal vein in patients with hepatocellular carcinoma: application of diffusion-weighted MR imaging. Radiology 2010; 254: 154–162.
- Brancatelli G, Baron RL, Federle MP, Sparacia G, Pealer K: Focal confluent fibrosis in cirrhotic liver: natural history studied with serial CT. AJR Am J Roentgenol 2009; 192: 1341–1347.
- Ohtomo K, Baron RL, Dodd GD 3rd, Federle MP, Miller WJ, Campbell WL et al.: Confluent hepatic fibrosis in advanced cirrhosis: appearance at CT. Radiology 1993; 188: 31–35.
- Ohtomo K, Baron RL, Dodd GD 3rd, Federle MP, Ohtomo Y, Confer SR: Confluent hepatic fibrosis in advanced cirrhosis: evaluation with MR imaging. Radiology 1993; 189: 871–874.
- Pokharel SS, Macura KJ, Kamel IR, Zaheer A. Current MR imaging lipid detection techniques for diagnosis of lesions in the abdomen and pelvis. Radiographics 2013; 33: 681–702.
- Mortelé KJ, Segatto E, Ros PR: The infected liver: radiologic-pathologic correlation. Radiographics 2004; 24: 937–955.
- Chung YE, Kim MJ, Park YN, Choi JY, Pyo JY, Kim YC et al.: Varying appearances of cholangiocarcinoma: radiologic-pathologic correlation. Radiographics 2009; 29: 683–700.
- Lee WJ, Lim HK, Jang KM, Kim SH, Lee SJ, Lim JH et al.: Radiologic spectrum of cholangiocarcinoma: emphasis on unusual manifestations and differential diagnoses. Radiographics 2001; 21: S97–S116.
- Shim M, Yang TY, Cho NG, Woo A, Kim E, Park K et al.: Hepatic infarction caused by portal vein thrombophlebitis misdiagnosed as infiltrative hepatic malignancy with neoplastic thrombus. Korean J Gastroenterol 2016; 68: 156–160.
- Jüngst C, Kramer J, Schneider G, Lammert F, Zimmer V: Subacute liver failure by pseudocirrhotic metastatic breast cancer infiltration. Ann Hepatol 2013; 12: 834–836.
- Young ST, Paulson EK, Washington K, Gulliver DJ, Vredenburgh JJ, Baker ME: CT of the liver in patients with metastatic breast carcinoma treated by chemotherapy: findings simulating cirrhosis. AJR Am J Roentgenol 1994; 163: 1385–1388.
- Jha P, Poder L, Wang ZJ, Westphalen AC, Yeh BM, Coakley FV: Radiologic mimics of cirrhosis. AJR Am J Roentgenol 2010; 194: 993–999.
- Ochiai T, Sonoyama T, Ichikawa D, Fujiwara H, Okamoto K, Sakakura C et al.: Poor prognostic factors of hepatectomy in patients with resectable small hepatocellular carcinoma and cirrhosis. J Cancer Res Clin Oncol 2004; 130: 197–202.
- Lopez RR Jr., Pan SH, Hoffman AL, Ramirez C, Rojter SE, Ramos H et al.: Comparison of transarterial chemoembolization in patients with unresectable, diffuse vs focal hepatocellular carcinoma. Arch Surg 2002; 137: 653–657; discussion 657–658.
- Jang ES, Yoon JH, Chung JW, Cho EJ, Yu SJ, Lee JH et al.: Survival of infiltrative hepatocellular carcinoma patients with preserved hepatic function after treatment with transarterial chemoembolization. J Cancer Res Clin Oncol 2013; 139: 635–643.
- Kim SB: Diffuse infiltrative hepatocellular carcinoma with portal vein tumor thrombosis completely cured by transcatheter arterial chemoembolization: case report with 8-year follow-up. Case Rep Gastroenterol 2016; 10: 623–628.
- Bruix J, Sherman M, American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020–1022.
- Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al.: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378–390.
- Kim HY, Park JW, Nam BH, Kim HK, Choi JI, Kim TH et al.: Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments. J Gastroenterol Hepatol 2011; 26: 1612–1618.
- Mehta N, Fidelman N, Sarkar M, Yao FY: Factors associated with outcomes and response to therapy in patients with infiltrative hepatocellular carcinoma. Clin Gastroenterol Hepatol 2013; 11: 572–578.
- Endo Y, Miyamoto M, Koujima T, Watanabe Y, Kawai T, Toda K et al.: [A case of advanced hepatocellular carcinoma with portal vein invasion successfully treated by sorafenib]. Gan To Kagaku Ryoho 2012; 39: 963–965.
- Ray EM, Sanoff HK: Optimal therapy for patients with hepatocellular carcinoma and resistance or intolerance to sorafenib: challenges and solutions. J Hepatocell Carcinoma 2017; 4: 131–138.
- Marino D, Zichi C, Audisio M, Sperti E, Di Maio M: Second-line treatment options in hepatocellular carcinoma. Drugs Context 2019; 8: 212577.
- Personeni N, Pressiani T, Rimassa L: Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib. Future Oncol 2019; 15: 2449–2462.
- Hsiao P, Hsieh KC, Chen YS, Hsu CC, Lo GH, Li YC et al.: Sorafenib with concurrent multiple-line therapies improves overall survival in advanced stage hepatocellular carcinoma. Medicine (Baltimore) 2019; 98: e16074.
- Reghupaty SC, Sarkar D: Current status of gene therapy in hepatocellular carcinoma. Cancers (Basel) 2019; 11.